Investors

Management Team

  • Geert Cauwenbergh, Dr. Med. Sc.

    Geert Cauwenbergh, Dr. Med. Sc.

    President and Chief Executive Officer

    Dr. Cauwenbergh was appointed President and Chief Executive Officer of RXi Pharmaceuticals Corporation in April of 2012. Prior to joining RXi, Dr. Cauwenbergh served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. He is a member of the board of directors of Cutanea Life Sciences and Moberg Pharmaceuticals. In 2005, Dr. Cauwenbergh was inducted into the New Jersey High-Tech Hall of Fame, and, from 2009 to 2010, he served as Chairman of the Board of Trustees of BioNJ. He has authored more than 100 publications and has been a guest editor for a number of books in mycology and infectious diseases. Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.
    • Alexey Eliseev, Ph.D.

      Alexey Eliseev, Ph.D.

      Chief Business Officer

      Dr. Eliseev was appointed Chief Business Officer in January 2017 to spearhead the business development initiatives for the Company's immunotherapy program. Dr. Eliseev is a highly accomplished leader with over 20 years of experience in academia, biotechnology industry and venture capital and most recently was the founder and CEO of MirImmune Inc. He also co-founded Therascope, later Alantos Pharmaceuticals, with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn, where he later became CTO of the company and President of its US division. Alantos was acquired by Amgen in 2007. Dr. Eliseev was also among the founders of AC Immune (Switzerland) and Boston BioCom LLC. Over recent years, he has worked with Maxwell Biotech Venture Fund as its Managing Director and ran the investment activity of the fund in the United States. Dr. Eliseev earned his PhD in Bioorganic Chemistry from Moscow State University and MBA from the MIT Sloan School of Management. Following postdoctoral research in Germany and in the US, he joined the faculty at SUNY Buffalo in 1995 where he was awarded tenure in 2000.

      • Gerrit Dispersyn, Dr. Med. Sc.

        Gerrit Dispersyn, Dr. Med. Sc.

        Chief Development Officer

        Dr. Gerrit Dispersyn was appointed Chief Development Officer in April 2017. Dr. Dispersyn is an accomplished leader in clinical, product and business development. He most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation. In this role, Gerrit was responsible for Integra’s global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra’s Senior Management Leadership team, and several of the company’s core teams for M&A projects. Dr. Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues, and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for RXi’s newly added focus on immuno-oncology and cell therapy. Prior to that role, he was the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. The company was a spin-out of Johnson & Johnson, and currently part of GlaxoSmithKline. There he led planning and implementation of all aspects of R&D operations and strategy; scientific, competitive and business intelligence; and alliance management. Dr. Dispersyn is the founder of Ingress, LLC, a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs. Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging, and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.

        • Karen Bulock, Ph.D.

          Karen Bulock, Ph.D.

          Vice President Research

          Dr. Bulock currently serves as Vice President Research for RXi Pharmaceuticals, Corporation. She joined Galena Biopharma, Inc. in October of 2007 and served as the Associate Director of Research until April 2012. Dr. Bulock has over twenty years of experience in assay development and discovery project management. Since joining RXi in 2011, and previously while at Galena, Dr. Bulock has managed several key programs, including the discovery and preclinical development of RXI-109, RXi’s first clinical candidate. Prior to joining RXi, Dr. Bulock spent several years leading assay development and screening projects to support small molecule drug discovery programs in the fields of metabolic disease and anti-infectives at CytRx Corporation and Essential Therapeutics, Inc. Dr. Bulock received a Ph.D. in Pharmacology from Yale University. Dr. Bulock has authored numerous scientific articles and is a co-inventor on four patent applications.